<?xml version='1.0' encoding='utf-8'?>
<document id="22221095"><sentence text="Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters."><entity charOffset="99-110" id="DDI-PubMed.22221095.s1.e0" text="nateglinide" /></sentence><sentence text="We have investigated the contributions of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to the hepatic uptake of nateglinide, and the possibility of drug-drug interactions via these transporters"><entity charOffset="129-140" id="DDI-PubMed.22221095.s2.e0" text="nateglinide" /></sentence><sentence text="" /><sentence text="Uptake studies using transporter-expressing HEK293 cells and cryopreserved human hepatocytes were performed to examine the contributions of each transporter" /><sentence text=" Inhibition studies using cryopreserved human hepatocytes were performed to examine the possibility of drug-drug interactions" /><sentence text="" /><sentence text="The rate of saturable hepatic uptake of nateglinide using human hepatocytes was 47"><entity charOffset="40-51" id="DDI-PubMed.22221095.s7.e0" text="nateglinide" /></sentence><sentence text="6%" /><sentence text=" A certain increase in uptake was observed in the examination using transporter-expressing HEK293 cells, indicating contributions of OATP1B1 and OATP1B3 to hepatic nateglinide uptake"><entity charOffset="164-175" id="DDI-PubMed.22221095.s9.e0" text="nateglinide" /></sentence><sentence text=" The 50% inhibitory concentration (IC50) values of nateglinide using cryopreserved human hepatocytes for uptake of estrone 3-sulfate (substrate of OATP1B1), and cholecystokinin octapeptide (substrate of OATP1B3) were 168 and 17"><entity charOffset="51-62" id="DDI-PubMed.22221095.s10.e0" text="nateglinide" /><entity charOffset="115-132" id="DDI-PubMed.22221095.s10.e1" text="estrone 3-sulfate" /><entity charOffset="203-210" id="DDI-PubMed.22221095.s10.e2" text="OATP1B3" /><pair ddi="false" e1="DDI-PubMed.22221095.s10.e0" e2="DDI-PubMed.22221095.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22221095.s10.e0" e2="DDI-PubMed.22221095.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22221095.s10.e0" e2="DDI-PubMed.22221095.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22221095.s10.e1" e2="DDI-PubMed.22221095.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22221095.s10.e1" e2="DDI-PubMed.22221095.s10.e2" /></sentence><sentence text="4 µmol/l, respectively" /><sentence text=" Moreover, ciclosporin inhibited saturable hepatic uptake of nateglinide with an IC50 value of 6"><entity charOffset="61-72" id="DDI-PubMed.22221095.s12.e0" text="nateglinide" /></sentence><sentence text="05 µmol/l" /><sentence text=" The calculated 1 + I(in,max,u) /IC50 values for inhibition of OATP1B1 and OATP1B3 by nateglinide, and the inhibition of saturable uptake of nateglinide by ciclosporin, were all close to 1, indicating a low clinical risk of drug-drug interaction with nateglinide taken up via OATP1B1 and OATP1B3"><entity charOffset="86-97" id="DDI-PubMed.22221095.s14.e0" text="nateglinide" /><entity charOffset="141-152" id="DDI-PubMed.22221095.s14.e1" text="nateglinide" /><entity charOffset="156-167" id="DDI-PubMed.22221095.s14.e2" text="ciclosporin" /><entity charOffset="251-262" id="DDI-PubMed.22221095.s14.e3" text="nateglinide" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e0" e2="DDI-PubMed.22221095.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e0" e2="DDI-PubMed.22221095.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e0" e2="DDI-PubMed.22221095.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e0" e2="DDI-PubMed.22221095.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e1" e2="DDI-PubMed.22221095.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e1" e2="DDI-PubMed.22221095.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e1" e2="DDI-PubMed.22221095.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e2" e2="DDI-PubMed.22221095.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22221095.s14.e2" e2="DDI-PubMed.22221095.s14.e3" /></sentence><sentence text="" /><sentence text="OATP1B1 and OATP1B3 may have contributed to the hepatic uptake of nateglinide, but the possibility of drug-drug interactions appeared to be low"><entity charOffset="66-77" id="DDI-PubMed.22221095.s16.e0" text="nateglinide" /></sentence><sentence text="" /></document>